Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge Setup Score
Trend Edge rates KALA Bearish with a Setup Score of 73, net conviction 38, actionability 142. How the Setup Score works →
Total Setup Score
73
Directional Bias
Bearish
Net Conviction
38
Actionability
142 (in range)
Key signals behind this score
Weak Trend — TE 20.00 (<40)
80wk Downtrend — falling+below (sma 204 vs px 2.64)
200wk Downtrend — falling+below (sma 386 vs px 2.64)
Earnings Headwind — ER in 0d · w1 med -4.4% p25 · winRate 40.0% · n35
About Kala Pharmaceuticals Inc
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesench… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: July 20, 2017
Headquarters: 1167 Massachusetts Avenue, Arlington, MA, United States, 02476
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$4.11
Near-term / short-term trend
Weekly
40-Week SMA
$71.53
Medium-term trend
Weekly
80-Week SMA
$204.17
Cyclical trend (business cycle)
Weekly
200-Week SMA
$386.16
Secular trend (multi-year)
Monthly
10-Month SMA
$25.59
Near-term monthly trend
Monthly
20-Month SMA
$178.04
Medium-term monthly trend
Monthly
40-Month SMA
$320.06
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$19.00
resistance
3.93x
2 months ago
$65.00
resistance
7.71x
5 months ago
$73.00
resistance
2.50x
7 months ago
$601.00
resistance
7.49x
8 months ago
Historical Earnings Reactions (35 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
-0.82%
-0.31%
31.43%
16.38%
-14.72%
1 Day
-0.54%
-1.59%
34.29%
64.70%
-14.29%
1 Week
-0.38%
-4.39%
40.00%
85.35%
-30.29%
2 Weeks
-5.05%
-6.21%
40.00%
39.91%
-49.14%
1 Month
-6.61%
-8.90%
23.53%
113.27%
-62.86%
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
1.4%
44.4%
9
Feb
-9.2%
22.2%
9
Mar
18.1%
55.6%
9
Apr
-12.9%
33.3%
9
May
-16.9%
22.2%
9
Jun
0.8%
50.0%
8
Jul
-2.5%
37.5%
8
Aug
4.4%
44.4%
9
Sep
-25.8%
0.0%
9
Oct
-21.9%
11.1%
9
Nov
3.9%
55.6%
9
Dec
57.0%
33.3%
9
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
-0.61%
41.9%
418
Tuesday
-0.32%
43.6%
461
Wednesday
0.19%
43.1%
457
Thursday
-0.12%
44.1%
449
Friday
0.17%
44.8%
451
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 0.6%
Insider Transactions — Smart Summary
Total insider ownership: 1.3%
12-Month Insider Activity Summary
Total Filings
11
Net Value
-$153,591.881
Net Shares Change
-1,064,499
% of Float
-5.7%
C-Suite Filings
7
Clusters Detected
2
Key Insiders
Name
Title
Net Value
Filings
Activity
BAKER BROS. ADVISORS LP
-$1.1M
1
1 sell
Iwicki Mark T
-$125,464.14
1
1 sell
Brazzell Romulus K
Head of Research and Development and Chief Medical Officer
-$59,857.35
2
1 sell
Bazemore Todd
-$55,920.02
2
1 sell
Reumuth Mary
CHIEF FINANCIAL OFFICER
-$42,103.861
2
1 sell
Kharabi Darius
CHIEF BUSINESS OFFICER
-$35,358.09
2
1 sell
Transaction Clusters
Period
Filings
Insiders
Net Value
Seniority
2025-06-26 – 2025-06-26
5
5
-$123,018.78
4 C-suite
2025-10-24 – 2025-10-24
5
5
-$248,724.951
3 C-suite
Significant Filings
Date
Insider
Title
Net Value
Price After
2025-10-24
Reumuth Mary
CHIEF FINANCIAL OFFICER
-$27,543.551
Transaction at $0.83, now +218.2%
2025-10-24
Kharabi Darius
CHIEF BUSINESS OFFICER
-$17,268.98
Transaction at $0.83, now +218.1%
2025-10-24
Brazzell Romulus K
Head of Research and Development and Chief Medical Officer
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Kala Pharmaceuticals Inc
(KALA) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.